Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Abstract: Although increased removal of chain-terminating inhibitors by pyrophosphorolysis and ATP-dependent unblocking correlated with reduced susceptibility of viruses with zidovudine-associated mutations, a reduction in the removal of chain-terminators was not observed, which would explain the increased drug susceptibility of mutants containing M184V plus zidovudine-associated mutations.
Abstract: An enzymatic analysis was undertaken to elucidate the mechanisms of altered drug susceptibilities of HIV-1 containing zidovudine-associated mutations in the presence or absence of M184V.
Abstract: However, analyses of single-cycle processivity of the mutant RT enzymes on heteropolymeric RNA templates showed that all M184V-containing mutant RT enzymes were less processive than wild-type
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Abstract: Adding abacavir to Combivir can be a safe and effective therapeutic option for patients, including those harbouring virus with the M184V mutation.
Abstract: An identical proportion of patients (74%) in each treatment group harboured virus with the M184V mutation after 12 weeks.
Abstract: At the time of intensification with abacavir, all 35 patients with evaluable isolates harboured HIV-1 containing M184V.
HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment.
Abstract: Another two patients partially responded to salvage regimens, both virologically and immunologically, and harboured the M184V mut in the RT gene.
Abstract: The M184V mut seemed to confer some viro-immunological benefit when associated with the Q151M mutation, compared with the latter alone.
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
PMID: 11517441
2001
The Journal of infectious diseases
Abstract: In group 2, all isolates carried the M184V mutation.
Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations.
Abstract: The least fit viruses were associated with the RT mutation M184I/V (11.6% less fit) and the PR mutations D30N (12.4% less fit) and M46I/L (21% less fit).
Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.
Abstract: Additionally, clinically important M184V mutation, which confers the viral resistance against 3TC and FTC, were studied by the same modeling system.
"Transient relapses (""blips"") of plasma HIV RNA levels during HAART are associated with drug resistance."
PMID: 11588503
2001
Journal of acquired immune deficiency syndromes (1999)
Abstract: Mutations in the RT and protease gene conferring resistance to one or more drugs were observed in 8 of 11 patients, 6 of whom had the M184V substitution.
"HIV-1 induction-maintenance at the lymph node level: the ""Apollo-97"" Study."
PMID: 11588509
2001
Journal of acquired immune deficiency syndromes (1999)
Abstract: In the patient with stable lymph node viral RNA, selection of the M184V mutation was demonstrated at this level before detection in plasma and low blood saquinavir levels were found throughout the study.
Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
PMID: 11602042
2001
AIDS research and human retroviruses
Abstract: In three patients, the only new mutation after failure was the RT mutation M184V.
HIV mutation literature information.
PMID: 
2001
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT